Synced daily from ClinicalTrials.gov via AACT. Last sync: .
10 Acoramidis clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 8 indications (including Amyloidosis & Cardiomyopathies) and 4,140 total planned enrollment. 5 Phase 3 Acoramidis trials, 2 Phase 4 are listed. 5 Acoramidis clinical trials are actively recruiting at 39 U.S. sites across 23 states. Most recent activity: NCT07116473 (Dec 2037).
Where to Participate: All Acoramidis Trial Sites in the U.S. (39 sites across 23 states)
Every actively recruiting Acoramidistrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
State
Facility
City
Trial
Map
CA
University of California, San Diego (UCSD) - Medical Center
ACO-REALA Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a Real-world Setting
ACO-SWITCHA Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis
A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis
A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a Real-world Setting
A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a Real-world Setting
A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis
10 Acoramidis clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 4 are actively recruiting participants. 3 are marked completed.
Are Acoramidis clinical trials recruiting in 2026?
Yes — 4 Acoramidis trials are actively recruiting in 2026, with 39 U.S. sites across 23 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Acoramidis being studied for?
Acoramidis is being studied for Amyloidosis, Cardiomyopathies, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Amyloid Cardiomyopathy, Transthyretin-Related and 12 more. The trials are grouped by indication on this page.
What phase is Acoramidis in?
Acoramidis clinical trials span 2 Phase 4, 5 Phase 3, 2 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Acoramidis clinical trials?
The lead sponsor across the most Acoramidis trials is Eidos Therapeutics, a BridgeBio company, with 2 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Acoramidisas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.